Out of all the bladder cancer cases, 32% were found to have any kind of FGFR activating mutation, of which 24% was FGFR2 or FGFR3 gene overexpression (>1 standard deviation across bladder cancer subset), 19% was FGFR2 or FGFR3 driver mutation, 5% was FGFR2 or FGFR3 gene amplification, and 3% was FGFR2 or FGFR3 fusion. This evidence concerns the gene FGFR2 and urinary bladder carcinoma.